

## **SUPPLEMENTARY FIGURES**

## **Supplementary Figure 1.**




**Supplementary Figure 1.** Flow diagram of patients in the trial.

## **Supplementary Figure 2.**



**Supplementary Figure 2.** There were no significant differences in  $\alpha$ -diversity measures between the chlorhexidine and no treatment arms. Change in  $\alpha$ -diversity (post- minus pre-treatment) in oral swabs comparing the two arms: (A) Chao (p=0.15), (B) Simpson (p=0.35), (C) Shannon (p=0.40); Change in  $\alpha$ -diversity (post- minus pre-treatment) in saliva comparing the two arms: (D) Chao (p=0.31), (E) Simpson (p=0.94), (F) Shannon (p=0.71); Comparison of  $\alpha$ -diversity from esophageal squamous tissue comparing the two arms: (G) Chao (p=0.78), (H) Simpson (p=0.08), (I) Shannon (p=0.34).

## **Supplementary Figure 3.**



**Supplementary Figure 3.** In  $\beta$ -diversity analyses, there was a non-significant trend towards a shift in the esophageal microbiome in the chlorhexidine arm (purple circles) as compared to the no treatment arm (light blue triangles): (A) Unweighted principal coordinates analysis (PERMANOVA p=0.08); and (B) weighted principal coordinates analysis (PERMANOVA p=0.07).